相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
Lihua E. Budde et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
F. L. Locke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Herve Tilly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/ refractory DLBCL: survival update and new extension cohort data
Laurie H. Sehn et al.
BLOOD ADVANCES (2022)
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
Sattva S. Neelapu et al.
NATURE MEDICINE (2022)
Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial
Rajat Bannerji et al.
LANCET HAEMATOLOGY (2022)
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Manali Kamdar et al.
LANCET (2022)
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
Franck Morschhauser et al.
BLOOD (2021)
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
Wyndham H. Wilson et al.
CANCER CELL (2021)
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
Grzegorz S. Nowakowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?
Arushi Khurana et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
Grzegorz S. Nowakowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
Martin Hutchings et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
Paolo F. Caimi et al.
LANCET ONCOLOGY (2021)
A comprehensive characterization of the cell-free transcriptome reveals tissue- and subtype-specific biomarkers for cancer detection
Matthew H. Larson et al.
NATURE COMMUNICATIONS (2021)
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Martin Hutchings et al.
LANCET (2021)
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Laurie H. Sehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report
Stuart E. Lacy et al.
BLOOD (2020)
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
George W. Wright et al.
CANCER CELL (2020)
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
Nagesh Kalakonda et al.
Lancet Haematology (2020)
Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)
Pieternella Johanna Lugtenburg et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
Laurie H. Sehn et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
Gilles Salles et al.
LANCET ONCOLOGY (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
Andrew D. Zelenetz et al.
BLOOD (2019)
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
Nancy L. Bartlett et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study
Herve Tilly et al.
LANCET ONCOLOGY (2019)
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
Andrew Davies et al.
LANCET ONCOLOGY (2019)
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction
David M. Kurtz et al.
CELL (2019)
Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
Daisuke Ennishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study
T. Wasterlid et al.
JOURNAL OF INTERNAL MEDICINE (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R
Catherine Lai et al.
LEUKEMIA & LYMPHOMA (2018)
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials
Matthew J. Maurer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (vol 24, pg 679, 2018)
Bjoern Chapuy et al.
NATURE MEDICINE (2018)
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
R. Schmitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
David M. Kurtz et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study
Kieron Dunleavy et al.
LANCET HAEMATOLOGY (2018)
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission
Daniel J. Landsburg et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma
Anupama Reddy et al.
CELL (2017)
Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis
Christina Howlett et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation
Haowei Sun et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
Maria Corinna A. Palanca-Wessels et al.
LANCET ONCOLOGY (2015)
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study
Mark Roschewski et al.
LANCET ONCOLOGY (2015)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson et al.
NATURE MEDICINE (2015)
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis
Adam M. Petrich et al.
BLOOD (2014)
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma
Patrick J. Stiff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Jia Ruan et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial
Christian Recher et al.
LANCET (2011)
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial
Frederic Peyrade et al.
LANCET ONCOLOGY (2011)
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study
G. S. Nowakowski et al.
LEUKEMIA (2011)
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
Laurie H. Sehn et al.
BLOOD (2007)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2006)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: An Italian multicenter randomized trial
M Martelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy
WH Wilson et al.
BLOOD (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: Randomized phase III EORTC study
HC Kluin-Nelemans et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)